Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 12:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Acute Gouty Arthritis Clear all

Completed Phase 3 Interventional Accepts healthy volunteers Results available

MPC-004 for the Treatment of an Acute Gout Flare

NCT00506883

View directory record Official record

Conditions: Gout
Interventions: High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose), Placebo Control; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older

Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 83
States / cities: Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more

Source: ClinicalTrials.gov public record

Updated Oct 31, 2012 · Synced May 22, 2026, 12:11 AM EDT

Completed Phase 3 Interventional Results available

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

NCT01356602

View directory record Official record

Conditions: Acute Gouty Arthritis
Interventions: Canakinumab pre-filled syringe, Canakinumab lyophilized powder, Triamcinolone Acetonide, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years

Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 69
States / cities: Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 62 more

Source: ClinicalTrials.gov public record

Updated Jan 28, 2014 · Synced May 22, 2026, 12:11 AM EDT

Completed Phase 3 Interventional Results available

Celebrex In Acute Gouty Arthritis Study

NCT00549549

View directory record Official record

Conditions: Arthritis, Gouty
Interventions: Indomethacin, Celecoxib; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 43
States / cities: Glendale, Arizona • Mesa, Arizona • Paradise Valley, Arizona + 37 more

Source: ClinicalTrials.gov public record

Updated Feb 20, 2021 · Synced May 22, 2026, 12:11 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic and Exploratory Electrocardiogram (ECG) Study

NCT01018420

View directory record Official record

Conditions: Pharmacokinetics
Interventions: Colchicine, Moxifloxacin; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Source: ClinicalTrials.gov public record

Updated Nov 30, 2009 · Synced May 22, 2026, 12:11 AM EDT

Completed No phase listed Observational

Prediction of 30-Day Readmission Using Machine Learning

NCT04849312

View directory record Official record

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older

Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Mar 16, 2026 · Synced May 22, 2026, 12:11 AM EDT

Terminated Phase 4 Interventional Results available

Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

NCT03636373

View directory record Official record

Conditions: Gout Attack
Interventions: Etanercept, Triamcinolone Acetonide; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 85 Years

Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Source: ClinicalTrials.gov public record

Updated Oct 26, 2023 · Synced May 22, 2026, 12:11 AM EDT

Completed No phase listed Observational

Prediction of Patient Deterioration Using Machine Learning

NCT05045742

View directory record Official record

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Traditional vital sign alarms versus the BioVitals Index vs the National Early Warning Score 2; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older

Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Mar 16, 2026 · Synced May 22, 2026, 12:11 AM EDT

Completed Not applicable Interventional

Rural Hospital-Level Care at Home for Acutely Ill Adults

NCT05256303

View directory record Official record

Conditions: Infections, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulation, Diabetes and Its Complications, End of Life/Desires Only Medical Management
Interventions: Home Hospital care, Traditional Hospital care; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older

Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Quincy, Illinois • Hazard, Kentucky

Source: ClinicalTrials.gov public record

Updated Nov 11, 2025 · Synced May 22, 2026, 12:11 AM EDT

Completed Phase 3 Interventional Results available

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

NCT01080131

View directory record Official record

Conditions: Acute Gout
Interventions: Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years

Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 96
States / cities: Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more

Source: ClinicalTrials.gov public record

Updated Jan 29, 2014 · Synced May 22, 2026, 12:11 AM EDT

Withdrawn No phase listed Observational

Prediction of Expected Length of Hospital Stay Using Machine Learning

NCT04784351

View directory record Official record

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Mar 16, 2026 · Synced May 22, 2026, 12:11 AM EDT

Recruiting Not applicable Interventional

Home Hospital for Suddenly Ill Adults

NCT03524222

View directory record Official record

Conditions: Infection, Heart Failure, COPD, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Home Hospitalization; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older

Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 2
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Mar 16, 2026 · Synced May 22, 2026, 12:11 AM EDT

Completed Phase 3 Interventional Results available

β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

NCT01470989

View directory record Official record

Conditions: Acute Gouty Arthritis Flares
Interventions: ACZ885, Triamcinolone acetonide 40 mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 33
States / cities: Anniston, Alabama • Mobile, Alabama • Norwalk, California + 28 more

Source: ClinicalTrials.gov public record

Updated Jul 8, 2021 · Synced May 22, 2026, 12:11 AM EDT

Completed Phase 2 Interventional Results available

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

NCT00819585

View directory record Official record

Conditions: Gout
Interventions: Canakinumab, Colchicine, Allopurinol, Placebo Matching Canakinumab, Placebo Matching Colchicine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 19
States / cities: Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more

Source: ClinicalTrials.gov public record

Updated Jul 16, 2018 · Synced May 22, 2026, 12:11 AM EDT

Completed Phase 4 Interventional

Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout

NCT01310673

View directory record Official record

Conditions: Gout, Gout Acute
Interventions: Allopurinol, Placebo; Drug
Lead sponsor: White River Junction Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older · Male only

Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2009
U.S. locations: 1
States / cities: White River Junction, Vermont

Source: ClinicalTrials.gov public record

Updated Mar 7, 2011 · Synced May 22, 2026, 12:11 AM EDT

Completed No phase listed Observational

AMPED Outcomes Registry of Post-ED Pain Management

NCT01626235

View directory record Official record

Conditions: Soft Tissue Injuries, Gouty Arthritis, Fractures, Ureteral Colic, Dysmenorrhea
Interventions: Not listed
Lead sponsor: Radnor Registry Research, Inc; Industry
Eligibility: 18 Years and older

Enrollment: 843 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 11
States / cities: Birmingham, Alabama • New Orleans, Louisiana • Jackson, Mississippi + 5 more

Source: ClinicalTrials.gov public record

Updated Mar 11, 2014 · Synced May 22, 2026, 12:11 AM EDT

Completed Phase 2 Interventional Accepts healthy volunteers

Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)

NCT04130204

View directory record Official record

Conditions: Gout
Interventions: DYV700, Placebo, Colchicine 0.6 mg; Drug
Lead sponsor: Dyve Biosciences, Inc.; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 284 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Poway, California

Source: ClinicalTrials.gov public record

Updated May 12, 2022 · Synced May 22, 2026, 12:11 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers

NCT06258213

View directory record Official record

Conditions: Gout, Acute Gout Flare, Gout Flares
Interventions: ABP-745, Placebo; Drug
Lead sponsor: Atom Therapeutics Co., Ltd; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Aug 16, 2025 · Synced May 22, 2026, 12:11 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of an Acute Gout Regimen

NCT01017042

View directory record Official record

Conditions: Pharmacokinetics
Interventions: colchicine tablets; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Fargo, North Dakota

Source: ClinicalTrials.gov public record

Updated Nov 19, 2009 · Synced May 22, 2026, 12:11 AM EDT

Withdrawn No phase listed Observational

Serum Potassium Prediction Using Machine Learning and Single-lead ECG

NCT07493798

View directory record Official record

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Potassium estimation algorithm; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Mar 24, 2026 · Synced May 22, 2026, 12:11 AM EDT

Completed Phase 3 Interventional

Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

NCT05586958

View directory record Official record

Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Interventions: Tigulixostat, Placebo; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 85 Years

Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 36
States / cities: Birmingham, Alabama • Covina, California • Clearwater, Florida + 31 more

Source: ClinicalTrials.gov public record

Updated Oct 28, 2025 · Synced May 22, 2026, 12:11 AM EDT

Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis

NCT03002974

View directory record Official record

Conditions: Acute Gouty Arthritis
Interventions: Anakinra 100 mg, Triamcinolone Acetonide 40 mg, Placebo to Anakinra 100 mg, Placebo to Triamcinolone Acetonide 40 mg; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 18 Years and older

Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 37
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 32 more

Source: ClinicalTrials.gov public record

Updated Jul 14, 2020 · Synced May 22, 2026, 12:11 AM EDT

Completed Phase 2 Interventional Results available

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

NCT00927810

View directory record Official record

Conditions: Gouty Arthritis
Interventions: Canakinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Source: ClinicalTrials.gov public record

Updated Jul 1, 2021 · Synced May 22, 2026, 12:11 AM EDT

Active, not recruiting Phase 2 Interventional

Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

NCT05690204

View directory record Official record

Conditions: Gout
Interventions: SAP-001; Drug
Lead sponsor: Shanton Pharma Pte. Ltd.; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 15
States / cities: Sacramento, California • San Diego, California • Denver, Colorado + 11 more

Source: ClinicalTrials.gov public record

Updated Nov 13, 2024 · Synced May 22, 2026, 12:11 AM EDT

Withdrawn Phase 2 Interventional

Apremilast Therapy for Acute Gouty Arthritis

NCT00997581

View directory record Official record

Conditions: Acute Gout
Interventions: apremilast, indomethacin SR; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older · Male only

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Source: ClinicalTrials.gov public record

Updated Apr 1, 2018 · Synced May 22, 2026, 12:11 AM EDT